熱門資訊> 正文

Protalix BioTherapeutics Q1收益预览

2026-05-13 02:07

PROTALIX生物療法(PLX) 0

Protalix BioTherapeutics (PLX) is scheduled to announce Q1 earnings results on Wednesday, May 13th, before market open.
The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $11.47M (+13.5% Y/Y).
Over the last 1 year, PLX has beaten EPS estimates 50% of the time and has beaten revenue estimates 100% of the time.

More on Protalix BioTherapeutics

Protalix: Elfabrio Struggles Against Oral Competition
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115
Protalix BioTherapeutics misses top-line and bottom-line estimates; gives FY26 outlook

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。